Functional Dyspepsia(FD) Was Studied
Conditions
Brief summary
The purpose of this clinical trial is to evaluate the efficacy of the herbal drug Weipi formula in treating functional dyspepsia (FD) in adults. It will also assess the safety of Weipi formula. The main questions the study aims to answer are: Does Weipi formula reduce participants' TCM syndrome scores? What medical issues might participants experience while taking Weipi formula? Researchers will compare Weipi formula with a placebo (an identical-looking substance without active drugs) to determine whether Weipi formula is effective in treating functional dyspepsia. Participant Procedures Participants will: Take Weipi formula or the placebo daily for 2 weeks. Visit the clinic once every week for examinations and tests. Record their symptoms and undergo measurements (e.g., pepsin levels).
Interventions
DRUGWeipi Formula（Wu SiSi Formula）
take Weipi Formula（Wu SiSi Formula） or the placebo daily for 2 weeks.
OTHERPlacebo
Take Weipi Formula（Wu SiSi Formula） or the placebo daily for 2 weeks.
Sponsors
Second Affiliated Hospital of Nanchang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* ① Meet the diagnostic criteria for epigastric fullness (Pi-Man) in Traditional Chinese Medicine (TCM); * Meet the Western diagnostic criteria for functional dyspepsia (FD), specifically postprandial distress syndrome (PDS) subtype, or meet both PDS and epigastric pain syndrome (EPS) subtypes but with PDS as the dominant presentation; * Age 18-80 years; * Willing to sign the informed consent form.
Exclusion criteria
* ① Gastroscopy findings: Benign or malignant digestive diseases (e.g., peptic ulcer, gastric cancer); * Severe organic diseases of the liver, gallbladder, spleen, or pancreas; * Severe organic diseases in other organ systems; * Pregnant or lactating women; ⑤ Patients with psychiatric disorders causing similar symptoms (e.g., schizophrenia, anxiety disorder, major depressive disorder); ⑥ Regular use (≥3 months) of NSAIDs and/or selective COX-2 inhibitors; ⑦ Potassium supplements taken within 2 weeks prior to enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TCM syndrome scores | From enrollment to the end of treatment at 2 weeks |
Countries
China
Outcome results
None listed